DeutschNewstral
Article
wsj.com on 2019-01-03 16:01
Bristol-Myers and Celgene: Side Effects Will Be Temporary
Related news
- Bristol-Myers Squibb to Acquire Celgenewsj.com
- Starboard Details Opposition to Bristol-Myers Deal for Celgenewsj.com
- FBristol-Myers Squibb investor opposes Celgene dealft.com
BÖRSEN-TICKER-Celgene gehen durch die Decke - Bristol-Myers verlierenReuters- HBristol-Myers Squibb Buying Celgene in $74B Dealhamodia.com
Bristol-Myers Squibb buying Celgene in $74B dealThe Wichita Eagle- Bristol-Myers wirbt bei Aktionären um Celgene-ÜbernahmeReuters
- FBristol-Myers Squibb defends Celgene takeover as ‘best path’ft.com
- BAt Long Last, Bristol-Myers Will Buy Celgene On Wednesdaybarrons.com
Bristol-Myers Squibb paying $74B for fellow drugmaker Celgenereviewjournal.com- Bristol-Myers to Shed Otezla, Carving Path for Celgene Dealwsj.com
- Bristol-Myers ringt um grünes Licht für Celgene-ÜbernahmeReuters
- FBristol-Myers Squibb to acquire Celgene for $74bnft.com
Bristol-Myers to Acquire Celgene in Deal Worth $74 BillionThe New York Times